Michael Sweeney

The exponential growth in the use of Direct-to-Patient clinical trials and the strategies pharmaceutical manufacturers should consider when implementing this model.

Q&A explores the evolution of community-based studies-and the related sample management, regulatory, compliance, and logistics support considerations.